

# Curriculum Vitae



Name: Bae, Jeong Mo

Degree: MD, PhD

Job title: Clinical Assistant Professor

Institution: Department of Pathology, Seoul National University Hospital

Interest: Cancer epigenetics, Molecular pathology, and Clinical sequencing

E-mail: [jeongmbae@gmail.com](mailto:jeongmbae@gmail.com)

## **Education and Qualification**

Feb, 23, 2007 - Medical Doctor, Ministry of Health & Welfare, Korea

Feb, 26, 2007 - Bachelor, Seoul National University College of Medicine

Feb, 25, 2011 - Master degree, Seoul National University College of Medicine

Mar, 2, 2012 - Specialist in Pathology, Ministry of Health & Welfare, Korea

Feb 2015 - Certified Scientist in BioMedical Informatics, Biomedical Informatics Training and Education Center, Seoul National University hospital

Feb, 24, 2017 - PhD., Seoul National University College of Medicine

## **Employment history**

Mar 1, 2007 ~ Feb 29, 2008 - Intern, Seoul National University Hospital, Seoul, Korea

Mar 1, 2008 ~ Feb 29, 2012 - Resident, Department of Pathology, Seoul National University Hospital, Seoul, Korea

May 1, 2012 ~ Apr 30, 2013 - Medical officer, Armed Force Medical Research Institute, Daejeon, Korea

May 1, 2013 ~ Apr 25, 2015 - Medical officer, Armed Force Capital Hospital, Kyeonggi-do, Korea

May 1, 2015 ~ Feb 29, 2016 - Clinical fellow, Department of Pathology, Seoul National University Hospital, Seoul, Korea

Mar 1, 2016 ~ Feb 28, 2017 - Assistant Professor, Department of Pathology, SMG-SNU Boramae Medical Center, Seoul, Korea

Mar 1, 2017 ~ Aug 31, 2017 – Assistant Professor, Department of Pathology, Seoul National University Hospital, Seoul, Korea

Sep 1, 2017 ~ Present – Clinical Assistant Professor, Department of Pathology, Seoul National University Hospital, Seoul, Korea

## **Awards and Honors**

Apr 24 2017 - Young Investigator Award in Basic Medical Research, Korean Medical Association

## **Recent Publications**

**Bae JM**, Kim JH, Kwak Y, Lee DW, Cha Y, Wen X, Lee TH, Cho NY, Jeong SY, Park KJ, Han SW, Lee HS, Kim TY, Kang GH. Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification, *Br J Cancer* 2017 Apr 11;1116(8):1012-1020

**Bae JM\***, Kim JH\*, Oh HJ, Park HE, Lee TH, Cho NY, Kang GH, Downregulation of acetyl-CoA synthetase 2 is a metabolic hallmark of tumor progression and aggressiveness in colorectal carcinoma, *Mod Pathol* 2017 Feb; 30(2):267-277

**Bae JM**, Kim JH, Kang GH. Molecular subtypes of colorectal cancer and their clinicopathologic features, with an emphasis on the serrated neoplasia pathway. *Arch of Pathol Lab Med.* 2016 May;140(5):406-12

Kim JH\*, **Bae JM\***, Cho NY, Kang GH, Distinct features between MLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway. *Oncotarget* 2016 Mar 22;7(12):14095-111

Kim JH\*, **Bae JM\***, Song YS, Cho NY, Lee HS, Kang GH, Clinicopathologic, molecular and prognostic implications of the loss of EPCAM expression in colorectal carcinoma. *Oncotarget* 2016 Mar 22;7(12):13372-87

**Bae JM\***, Rhee YY\*, Kim KJ, Wen X, Song YS, Cho NY, Kim JH, Kang GH, Are clinicopathological features of colorectal cancers with methylation in half of CpG island methylator phenotype panel markers different from those of CpG island methylator phenotype-high colorectal cancers? *Hum Pathol* 2016 Jan;47(1):85-94

**Bae JM**, Lee JY, Cho J, Lim SA, Kang GH. Synchronous mucosal Schwann-cell hamartomas in a young adult suggestive of mucosal Schwann-cell hamartomatosis: a case report. *BMC Gastroenterol* 2015 Oct 6;15(1):128

**Bae JM**, Kim JH, Rhee YY, Cho NY, Kim TY, Kang GH, Annexin A10 expression in colorectal cancers with emphasis on the serrated neoplasia pathway. *World J Gastroenterol.* 2015 Sep 7;21(33):9749-57

**Bae JM\***, Lee TH\*, Cho NY, Kim TY, Kang GH. Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients. *World J Gastroenterol.* 2015 Feb 7;21(5):1457-67

**Bae JM**, Kim JH, Cho NY, Kim TY, Kang GH. Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumor location. *Br J Cancer.* 2013 Aug 20;109(4):1004-12

**Bae JM**, Kim JH, Kang GH. Epigenetic alterations in colorectal cancer: the CpG island methylator phenotype. *Histol Histopathol.* 2013 May;28(5):585-95

\*: co-first author